{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:41:14Z","timestamp":1788352874947,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s13555-024-01268-z","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T18:01:43Z","timestamp":1727892103000},"page":"2877-2887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Descriptive, Post\u00a0Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis"],"prefix":"10.1007","volume":"14","author":[{"given":"Andrew F.","family":"Alexis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Espaillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"Kaldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne M.","family":"Dilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeeta","family":"Sinvhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chudy","family":"Nduaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lockshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"issue":"1","key":"1268_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jaad.2004.07.045","volume":"52","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52(1):23\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1268_CR2","first-page":"16","volume":"7","author":"AF Alexis","year":"2014","unstructured":"Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014;7(11):16\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"1268_CR3","first-page":"271","volume":"71","author":"SC Taylor","year":"2003","unstructured":"Taylor SC. Epidemiology of skin diseases in people of color. Cutis. 2003;71(4):271\u20135.","journal-title":"Cutis"},{"issue":"5","key":"1268_CR4","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.jid.2021.09.031","volume":"142","author":"A Klopot","year":"2022","unstructured":"Klopot A, et al. Transcriptome analysis reveals intrinsic proinflammatory signaling in healthy African American Skin. J Investig Dermatol. 2022;142(5):1360-1371.e15.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"1268_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","volume":"19","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-White Racial\/Ethnic Groups. Am J Clin Dermatol. 2018;19(3):405\u201323.","journal-title":"Am J Clin Dermatol"},{"key":"1268_CR6","doi-asserted-by":"publisher","DOI":"10.5070\/D3247040909","author":"D Yan","year":"2018","unstructured":"Yan D, et al. A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol Online J. 2018. https:\/\/doi.org\/10.5070\/D3247040909.","journal-title":"Dermatol Online J"},{"issue":"6","key":"1268_CR7","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jaad.2022.03.067","volume":"87","author":"S McKenzie","year":"2022","unstructured":"McKenzie S, et al. Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color. Part II: differences in clinical presentation and disparities in cutaneous disorders in skin of color. J Am Acad Dermatol. 2022;87(6):1261\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1268_CR8","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1016\/j.jid.2022.02.013","volume":"142","author":"J Takeshita","year":"2022","unstructured":"Takeshita J, et al. Health-Related QOL Differs by Race\/Ethnicity in North American Patients with Psoriasis: results from PSOLAR. J Investig Dermatol. 2022;142(9):2528-2531.e3.","journal-title":"J Investig Dermatol"},{"issue":"2","key":"1268_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ced.14871","volume":"47","author":"MV Ha","year":"2022","unstructured":"Ha MV, Wong C. Racial representation in clinical trials for dermatological new molecular entities. Clin Exp Dermatol. 2022;47(2):386\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1268_CR10","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1016\/j.jaad.2022.01.043","volume":"86","author":"JW Ricardo","year":"2022","unstructured":"Ricardo JW, Lipner SR. Under-representation of racial and ethnic minorities in nail psoriasis randomized clinical trials: a call to action. J Am Acad Dermatol. 2022;86(6):e267\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1268_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000520469","volume":"8","author":"JW Ricardo","year":"2022","unstructured":"Ricardo JW, Qiu Y, Lipner SR. Racial, ethnic, and sex disparities in nail psoriasis clinical trials: a systematic review. Skin Appendage Disord. 2022;8(3):171\u20138.","journal-title":"Skin Appendage Disord"},{"issue":"21","key":"1268_CR12","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1001\/jama.2021.16680","volume":"326","author":"M Lolic","year":"2021","unstructured":"Lolic M, et al. Racial and ethnic representation in US clinical trials of new drugs and biologics, 2015\u20132019. JAMA. 2021;326(21):2201\u20133.","journal-title":"JAMA"},{"issue":"2","key":"1268_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/17407745221149118","volume":"20","author":"MM Reid","year":"2023","unstructured":"Reid MM, et al. Demographic diversity of US-based participants in GSK-sponsored interventional clinical trials. Clin Trials. 2023;20(2):133\u201344.","journal-title":"Clin Trials"},{"key":"1268_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106421","volume":"106","author":"M Rottas","year":"2021","unstructured":"Rottas M, et al. Demographic diversity of participants in Pfizer sponsored clinical trials in the United States. Contemp Clin Trials. 2021;106: 106421.","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"1268_CR15","first-page":"1215","volume":"315","author":"S Narla","year":"2023","unstructured":"Narla S, et al. Racial disparities in dermatology. Arch Dermatol Res. 2023;315(5):1215\u201323.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"1268_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jaad.2023.04.011","volume":"89","author":"J Mineroff","year":"2023","unstructured":"Mineroff J, Nguyen JK, Jagdeo J. Racial and ethnic underrepresentation in dermatology clinical trials. J Am Acad Dermatol. 2023;89(2):293\u2013300.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1268_CR17","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/bjd.20595","volume":"185","author":"KA Papp","year":"2021","unstructured":"Papp KA, et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021;185(6):1135\u201345.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1268_CR18","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jaad.2022.05.038","volume":"87","author":"CW Enos","year":"2022","unstructured":"Enos CW, et al. Similar response to biologic therapy across racial and ethnic groups among patients with psoriasis enrolled in the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2022;87(5):1087\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1268_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00403-022-02324-4","volume":"315","author":"JE Ferguson","year":"2023","unstructured":"Ferguson JE, et al. Racial\/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review. Arch Dermatol Res. 2023;315(1):41\u201350.","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"1268_CR20","first-page":"804","volume":"18","author":"AF Alexis","year":"2019","unstructured":"Alexis AF, et al. Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. J Drugs Dermatol. 2019;18(8):804\u201313.","journal-title":"J Drugs Dermatol"},{"issue":"14","key":"1268_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1056\/NEJMp2215609","volume":"388","author":"AL Schwartz","year":"2023","unstructured":"Schwartz AL, et al. Why diverse clinical trial participation matters. N Engl J Med. 2023;388(14):1252\u20134.","journal-title":"N Engl J Med"},{"issue":"2","key":"1268_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijwd.2020.12.018","volume":"7","author":"KL Perlman","year":"2021","unstructured":"Perlman KL, et al. Skin of color lacks representation in medical student resources: a cross-sectional study. Int J Womens Dermatol. 2021;7(2):195\u20136.","journal-title":"Int J Womens Dermatol"},{"issue":"1","key":"1268_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jaad.2017.07.052","volume":"78","author":"AH Fischer","year":"2018","unstructured":"Fischer AH, et al. Health care utilization for psoriasis in the United States differs by race: an analysis of the 2001\u20132013 medical expenditure panel surveys. J Am Acad Dermatol. 2018;78(1):200\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1268_CR24","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jamadermatol.2018.3114","volume":"154","author":"R Tripathi","year":"2018","unstructured":"Tripathi R, et al. Association of demographic and socioeconomic characteristics with differences in use of outpatient dermatology services in the United States. JAMA Dermatol. 2018;154(11):1286\u201391.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1268_CR25","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/jamadermatol.2022.2426","volume":"158","author":"KK Wu","year":"2022","unstructured":"Wu KK, Armstrong AW. Differences in face-to-face time spent with a dermatologist among patients with psoriasis based on race and ethnicity. JAMA Dermatol. 2022;158(10):1210\u20132.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1268_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjd.19876","volume":"185","author":"WT Hodges","year":"2021","unstructured":"Hodges WT, et al. Biologics utilization for psoriasis is lower in black compared with white patients. Br J Dermatol. 2021;185(1):207\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1268_CR27","first-page":"650","volume":"112","author":"MA Bell","year":"2020","unstructured":"Bell MA, et al. Racial and ethnic disparities in access to emerging and frontline therapies in common dermatological conditions: a cross-sectional study. J Natl Med Assoc. 2020;112(6):650\u20133.","journal-title":"J Natl Med Assoc"},{"issue":"11","key":"1268_CR28","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s13555-022-00811-0","volume":"12","author":"G Yadav","year":"2022","unstructured":"Yadav G, et al. Unmet need in people with psoriasis and skin of color in Canada and the United States. Dermatol Ther. 2022;12(11):2401\u201313.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01268-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01268-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01268-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:04:31Z","timestamp":1729008271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01268-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1268"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01268-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A Alexis has received grants from Leo, Amgen, Galderma, Arcutis, Dermavant, AbbVie, and Castle, has served on advisory boards or as an consultant for Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Ortho, L\u2019Oreal, BMS, Bausch health, UCB, Vyne, Arcutis, Janssen, Allergan, Almirall, AbbVie, Amgen, VisualDx, Eli Lilly, Swiss American, Cutera, Cara, EPI, Incyte, Castle, Apogee, Canfield, and Alphyn, has received speaker fees from Regeneron, SANOFI-Genzyme, BMS, L\u2019Oreal, Janssen, and J&J, has received royalties from Springer, Wiley-Blackwell, and Wolters Kluwer Health and has received an equipment loan from Aerolase. M Gooderham has received speaker or consulting fees and\/or research grants from: AbbVie, Amgen, Akros, Aslan, AnaptysBio, Aristea, Arcutis, Bausch Health, BMS, Boehringer Ingelheim, Cara Therapeutics, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Mooklake, Meiji, Nimbus, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, UCB. S G Kwatra has received speaker or consulting fees and\/or research grants AbbVie, Celldex Therapeutics, Galderma, Incyte Corporation, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Kiniksa Pharmaceuticals and has served as an investigator for Galderma, Kiniksa Pharmaceuticals, Pfizer Inc., and Sanofi. A Amin has received speaker or consulting fees from AbbVie, Eli Lilly, Janssen, Dermavant, Leo Pharma, Regeneron, Sanofi\/Genzyme, UCB, Amgen, BMS, and Pfizer. S Taylor has served on advisory boards for AbbVie, Avita Medical, Beiersdorf, Eli Lilly, EPI Health, Evolus, Galderma, Hugel, Incyte, Johnson & Johnson, L\u2019Oreal, Medscape, Pfizer, Scientis, UCB and Vichy Laboratories, has served as an investigator for Allergan, Concert Pharamceuticals, Croma-Pharma GmbH Austria, Eli Lilly, Pfizer, and Sun Pharma, has served as a constulta form Armis Biopharma, Beiersdof, Bristol-Meyers Squibb, Cara Therapeutics, Dior, GloGetter, Piction Health, and Sanofi, has received speaker fees for Beiersdort, Catalyst Medical Education, Medscape, and MJH Life Sciences, and serves on the board of directors and has received employee fees from Mercer Strategies. R Espaillat, T Rettig, M Kaldas, T Wu, L Shi, DM Dilley, R Sinvhal, and C Nduaka are full-time salaried employees of AbbVie and may own stock\/options. B Lockshin has received speaker and\/or consulting fees and\/or research grants from AbbVie, Novartis, Eli Lilly, Sanofi, Regeneron, Incyte, Leo, UCB, DermTech, Strata Skin Sciences, Corrona Registry, Boehringer Ingelheim, Pfizer, Franklin Bioscience, Trevi Therapeutics, Inc., Vanda, Celgene, Galderma, Amgen, and Dermira.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The LIMMitless study is being conducted in accordance with the Good Clinical Practice Guideline as defined by the International Conference on Harmonisation, the Declaration of Helsinki and\/or all applicable federal and local regulations, and all patients provided written informed consent. All protocols were approved by an institutional review board (Quorom Review IRB, Seattle, WA, USA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}